FDA Approves Secukinumab for Adolescents With Moderate to Severe Hidradenitis Suppurativa - Top-Institutions - MDSpire

FDA Approves Secukinumab for Adolescents With Moderate to Severe Hidradenitis Suppurativa

Secukinumab becomes the only interleukin-17A inhibitor approved for pediatric patients aged 12 years and older with moderate to severe hidradenitis suppurativa.

  • By

  • Kathryn Wighton

  • March 13, 2026

  • 2 min

Share

Top Institutions in Pediatrics

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Dermatology
    • Immunology
    • Pediatric Dermatology

  • #2

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Dermatology
    • Immunology

  • #3

    University of Pennsylvania (Perelman School of Medicine)
    University of Pennsylvania (Perelman School of Medicine)

    Philadelphia, PA

    Key Differentiators

    • Dermatology
    • Pediatric Dermatology
    • Immunology

  • #4

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Dermatology
    • Immunology

  • #5

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Dermatology
    • Pediatric Dermatology

Original Source(s)

FDA Approves Secukinumab for Adolescents With Moderate to Severe Hidradenitis Suppurativa

  • by Kathryn Wighton

  • March 13, 2026

Related Content

Partly intraoperative cell salvage in pediatric craniocerebral trauma: effects on coagulation function, allogeneic blood requirements, and clinical outcomes — a propensity score-matched retrospective cohort study

Laparoscopic intracavitary catheterization combined with bleomycin quadruple sclerotherapy for retroperitoneal lymphatic malformations: a single-center case series

Highlighting the value of polymyography in childhood onset movement disorders